As AstraZeneca Makes U-Turn On Covishield Side Effects, A Lookback At The COVID Vaccine’s Controversies

AstraZeneca admits that people may have rare side effects from Covishield vaccine, 1 billion 70 crore doses of Covishield administered in India, but no need to fear!
During the Corona pandemic, Covishield, developed by AstraZeneca and Oxford University, was produced by the Serum Institute of India and was widely administered to people in the country.

AstraZeneca’s Statement on Side Effects

New Delhi: AstraZeneca, the company manufacturing anti-Covid-19 vaccine ‘Covishield’, has itself admitted that people taking it may have rare side effects. According to the report of The Telegraph (UK), British pharma giant AstraZeneca has admitted that its Covid vaccine may have rare side effects. The vaccine manufacturer has said in court documents that Covishield can, in rare cases, cause a condition that can lead to blood clots and low platelet counts.

Covishield, developed by AstraZeneca and Oxford University, was produced by the Serum Institute of India during the pandemic and was widely administered to people in the country. AstraZeneca is facing several lawsuits in Britain over claims that its vaccine has caused several deaths and serious injuries. In 51 cases in the UK High Court, victims are demanding damages of up to 100 million pounds.

A Case Study: Jamie Scott’s Experience

Jamie Scott, the first complainant in the case, had alleged that he was given the vaccine in April 2021, which caused permanent brain injury after blood clotting. He claimed that it made it difficult for him to work… The hospital even told his wife three times that he was going to die.

Astra-Zeneca has disputed the claims, but acknowledged in a court document in February that Covishield “can, in very rare cases, cause TTS,” the report said. TTS (Thrombosis with Thrombocytopenia Syndrome) causes blood clots and low blood platelet counts in humans.

The Politics of Telangana – A Deep Dive

The Medical Condition: Understanding TTS

“It is believed that the AZ vaccine may, in very rare cases, cause TTS. Additionally, TTS may occur in the absence of the AZ vaccine (or any vaccine),” AstraZeneca said. AstraZeneca agreed to the legal defense of Scott’s claim, which could lead to payments to victims and bereaved relatives.

The latest admission also contradicts the company’s 2023 stance, in which it told Jamie Scott’s lawyers: “We do not accept that TTS is caused by the vaccine on a moderate scale.” However, AstraZeneca has denied lawyers’ claims that the vaccine is “defective” and that its efficacy has been “grossly overstated”.

Conclusion: Navigating the Complexities of Vaccine Safety

As we have explored, the journey of Covishield, from a beacon of hope during the pandemic to the center of legal debates, underscores the complexities of vaccine safety. AstraZeneca’s recent admission about the rare side effects of TTS brings to light the importance of transparency and ongoing vigilance in public health initiatives.

While the cases presented in court reflect individual experiences, they serve as a reminder that vaccine development is an intricate balance of risk and benefit. The acknowledgment of TTS as a potential side effect, albeit rare, is a step towards greater understanding and management of vaccine-related complications.

Leave a Comment